NervGen Pharma Corp.
Symbol:
TSXV: NGEN
OTCQX: NGENF
Market Cap:
121M
Purpose
Raise Awareness, Open Market Buying
Sector:
143
Summary:
- Proof-of-concept Phase 1b/2a clinical trial initiated in the US
- Initial readout from trial expected in summer 2024
- Targeting indications of high unmet need beginning with spinal cord injury and including stroke, ALS, MS, and Alzheimer’s disease